Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries
Partners Expect To Launch Products Between 2023 And 2026
Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.
You may also be interested in...
Finland’s Orion is continuing to await the potentially uplifting effect of its biosimilar partnership with Aurobindo’s CuraTeQ Biologics, after another tricky year.
Aurobindo has filed for its second oncology biosimilar with the EMA in January 2022, as the company remains on track to develop its biosimilars portfolio in both oncology and immunology segments. The company has also launched seven products, including four injectables, in its financial third quarter ended 31 December 2021.
What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.